E

Exelixis

Biopharmaceutical oncology company developing cancer therapies

DMPK Director

Quantitative Biology & BiostatisticsUpdated on Nov 10
Full-timeAlameda, CA, USAIn-person

About the Job

Requirements

  • A PhD degree in Drug Metabolism, Pharmacokinetics, Pharmaceutical Sciences, or another relevant field, and at least 8 years of relevant pharmaceutical-industry DMPK experience; an equivalent combination of education and experience is also acceptable.
  • Expert knowledge of in vitro and in vivo ADME studies.
  • Experience managing external DMPK work at contract research organizations.
  • Extensive experience identifying clinical candidates by balancing ADME, pharmacology, and toxicology properties and progressing molecules into clinical trials.
  • Solid experience using physiologically based and empirical modeling and simulation techniques to characterize drug-drug interactions and biopharmaceutics liabilities.
  • Experience submitting IND, NDA, and BLA applications and global marketing applications.
  • Extensive scientific and technical knowledge of drug metabolism and drug transporters, including enzymology, enzyme kinetics, and in vitro to in vivo extrapolation.
  • Demonstrated independent thought and creativity in science and drug discovery.
  • Experience applying emerging science and technologies to strengthen and improve research capabilities.
  • In-depth knowledge of current practices and issues in DMPK, including regulatory requirements, PKPD, and translational sciences.
  • Able to work effectively with multidisciplinary teams.
  • Able to analyze diverse-scope problems and complex ADME issues involving evaluation of identifiable and variable factors.
  • Able to exercise independent judgment in selecting methods, techniques, and evaluation criteria to obtain results.
  • Able to find creative solutions to unique and complex problems.

Responsibilities

  • Lead IND- and NDA-enabling ADME work, characterize the ADME properties of molecules, collaborate to establish in vitro to in vivo correlations, and ensure DMPK studies and analyses are consistent with regulatory guidance.
  • Analyze and interpret preclinical pharmacokinetic and pharmacodynamic data to inform drug-development decisions.
  • Partner with Discovery to develop translational ADME strategies and collaborate on their rollout and execution, integrating knowledge from Discovery to Development.
  • Collaborate with Translational Medicine, CMC, Toxicology, Clinical Development, and Regulatory to deliver project and corporate objectives.
  • Prepare regulatory documents, including IND, CTA, and NDA filings; prepare DMPK components of nonclinical and clinical study protocols, study reports, and investigator brochures.
  • Support functional-area reviews for due-diligence evaluations.
  • Present scientific findings to senior management, project teams, and internal and external collaborators.
  • Stay current with DMPK research advances and identify and integrate emerging science to advance the portfolio.
  • Maintain external scientific visibility through publications.
  • Contribute to a science-driven, goal-oriented culture that values innovation, teamwork, agility, transparency, accountability, and empowerment.
  • Perform other duties as assigned and comply with applicable policies and standards.

Desired Qualifications

  • Experience with antibody-drug conjugates is a plus.

About the Company

Exelixis

Biopharmaceutical oncology company developing cancer therapies

Exelixis develops and commercializes medicines for cancer. Its products aim to treat advanced cancers, including renal cell carcinoma, by targeting multiple biological pathways and supporting combination regimens to achieve effective, tolerable, and durable responses. The company generates revenue from sales of approved therapies and strategic partnerships, backed by extensive research, clinical trials, and regulatory approvals to bring new drugs to market. Compared with peers, Exelixis focuses on a pipeline that combines multi-pathway targeting with combination therapies to improve patient outcomes. Its overall goal is to advance cancer treatment and offer patients better chances of remission through its ongoing drug development programs.

Company size
1,001-5,000
Company stage
IPO
Headquarters
San Francisco, CA
Founded
1994

Recently Posted Jobs

Explore more opportunities at Exelixis

See more jobs